November 1, 2021 -- Incyte plans to highlight clinical study data for its oncology portfolio at the upcoming Society for Immunotherapy of Cancer (SITC) 2021 annual meeting in Washington, DC, November 12-13, 2021.
The data will be presented in an oral presentation and two poster presentations, Incyte said. The presentations include the following:
- An oral presentation of abstract No. 529: "Phase 1 Study of INCB086550, an Oral PD-L1 Inhibitor, in Immune Checkpoint-Naive Patients With Advanced Solid Tumors"
- A poster for abstract No. 545: "A Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma"
- A poster for abstract No. 956: "Retifanlimab (INCMGA00012) in Patients With Recurrent MSI-H or dMMR Endometrial Cancer: Results From the POD1UM-101 Study"
Copyright © 2021 scienceboard.net